KalshiBeschikbaarheid controlerenKYC vereist2% kostenHuidige impliciete kansBefore Jan 1, 2027 17%-11.0%Koploper van 5 uitkomsten
Marktkwaliteit
28 / 100
Lage kwaliteit24u volume
€ 5,1
Liquiditeit
€ 73,8
Lage liquiditeitBied / Laat
16.0% / 19.0%
Spread
18.8%
Brede spreadMarktdata
Bijgewerkt 7 minuten geleden
14 mei 26, 2:001 jan 27, 4:59
Trends
Gekozen uitkomst
Before Jan 1, 202717%
Ook beschikbaar op Polymarket
FDA approves Retatrutide this year?
1.0%6mnd
-0.0%12%
+0.0%89%
52 • Gemiddelde kwaliteitBrede spreadGemiddelde liquiditeit
Totaal volume€ 493,2K
24u volume€ 238,8
POLYMARKETRegels
If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2027, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals:
Vergelijkingsgegevens zijn alleen informatief. Prijzen en liquiditeit kunnen variëren.
Gerelateerde Markten
Hantavirus pandemic in 2026?
€ 145,3KJa: 5%POLYMARKET
POLYMARKET
New pandemic in 2026?
€ 16,6KJa: 10%POLYMARKET
POLYMARKET
How many movies will gross >$1 billion in 2026?
€ 1,3K0-3: 5.7%MANIFOLD MARKETS
MANIFOLD MARKETSWhich disease will be eradicated next in humans?
€ 462,5Polio: 26.7%MANIFOLD MARKETS
MANIFOLD MARKETS
When, where or how will Trump die?
€ 137,82025: 0%MANIFOLD MARKETS
MANIFOLD MARKETSActief in deze onderwerpen
Gerelateerd Nieuws
Chainalysis reveals $100 million peptide market built on cryptoCrypto News
Gray peptide vendors embrace stablecoins as safety fears deepenCrypto News
OpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.News
Brian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto NewsRegels
If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2027, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals: